Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Farmacia Hospitalaria
versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343
Resumen
FERNANDEZ-CANABATE, Eva y FERNANDEZ-CANABATE, Sonia. Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin’s lymphoma. Farm Hosp. [online]. 2018, vol.42, n.1, pp.20-21. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.10830.
Clinical case:
A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were administered. 12 months after the last intravitreal rituximab dose, signs and symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab administration were not observed.
Discussion:
Intravitreal rituximab is an effective and safe treatment of intravitreal lymphoma, by inducing complete remission; it could be a good alternative to other therapeutic options with greater number of serious complications.
Palabras clave : Rituximab; Primary colon lymphoma; Diffuse large B cell lymphoma; Vitreoretinal lymphoma; Intravitreal injection; Non Hodgkin’s lymphoma.